Global Currency Shuffle: Euro Dips, Yen Recovers, and Markets Await Key Economic Signals 
Ether Price Rises Despite $1.3B Whale Sell-Off, Targets $3,700 Breakout 
We rated the urban forests of 8 global cities – only Singapore passed the 30% canopy test 
Siri's AI Upgrade in iOS 19 May Signal Apple's Split from OpenAI and ChatGPT 
Senator Lummis Pushes for 1M BTC in US Reserve to Slash Debt, Preserve Dollar Dominance 
Texas Considers Bitcoin Reserve Legislation Amid Push for US Crypto Mining Security 
TikTok CEO Turns to Musk for Guidance Amid Trump Policy Concerns, WSJ Reports 
Oil Prices Soar to 2-Week High as Russia Fires Hypersonic Missiles, Escalating Ukraine Conflict 
Shiba Inu Burn Rate Explodes 49,646% as SHIB Price Climbs 10% in Stunning Market Rally 
Federal Workers Fear Mass Firings as Trump, Musk, and Ramaswamy Promise Government Overhaul: 'Billions Could Be Cut!' 
China’s Pony AI Pursues $4.55 Billion Valuation in Ambitious US IPO to Lead Robotaxi Surge 
New ‘best practice’ principles for superannuation products are coming. We asked a panel of experts what should be included 
Fed's Goolsbee Expects Rates to Drop 'Fair Bit Lower,' Cautions on Slowing Cuts 
$18 XRP Prediction Gains Traction as Wave 3 Builds Toward $5 Surge Before 2024 
Amazon's $4 Billion Anthropic Deal Supercharges AI Race Against Microsoft and Google 
Xiaomi's Second Electric SUV to Challenge Tesla Model Y in Q1 2025, Report Reveals 
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.
